NeuroVice
Private Company
Funding information not available
Overview
NeuroVice is a private, commercial-stage medical device company that has developed and launched PATI®, the first FDA-cleared oral device for seizure protection. The product addresses a critical unmet need in epilepsy and seizure care by providing a safe, clinically-backed alternative to dangerous makeshift methods like spoons or towels. The company operates a direct-to-consumer and B2B model, leveraging telehealth partnerships and pharmacy distributors for prescription fulfillment. NeuroVice is positioned in the digital health and neuroscience sectors, targeting a large global patient population suffering from seizure-related oral trauma.
Technology Platform
Patented, single-use oral medical device platform designed for physical protection and airway management during seizures. Features include tongue protection, secure fit, and maintained airflow.
Opportunities
Risk Factors
Competitive Landscape
PATI® faces competition from improvised methods (spoons, towels) which are the historical standard of care, albeit unsafe. There are no other FDA-cleared dedicated oral devices for seizure protection mentioned, giving NeuroVice a first-mover advantage. Potential future competitors include other medical device startups or established neurology-focused companies that may develop similar protective solutions.